The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Changes in body composition during neoadjuvant platinum-based chemotherapy associations prior to radical cystectomy: Implications for chemotherapy-associated adverse events and oncologic outcomes.
 
Reno Maldonado
No Relationships to Disclose
 
Florian J. Fintelmann
No Relationships to Disclose
 
Jan Peter Marquardt
No Relationships to Disclose
 
Ryan Blair O'Malley
No Relationships to Disclose
 
Sarah K. Holt
No Relationships to Disclose
 
Steven Ngo
No Relationships to Disclose
 
Leonidas Nikolaos Diamantopoulos
No Relationships to Disclose
 
Grace Laidlaw
No Relationships to Disclose
 
George R. Schade
No Relationships to Disclose
 
Daniel W. Lin
Consulting or Advisory Role - Astellas Pharma; Clovis Oncology; Dendreon
Research Funding - GenomeDx (Inst); Genomic Health (Inst); Magforce (Inst); MDxHealth (Inst)
 
Jonathan L. Wright
Speakers' Bureau - Virginia Mason Medical Center
Research Funding - Altor BioScience; Janssen Oncology; Merck; Nucleix
Patents, Royalties, Other Intellectual Property - Royalties from UpToDate for chapter I wrote.
Other Relationship - Movember Foundation; UpToDate
 
John L. Gore
Research Funding - Ferring
 
Yaw A. Nyame
No Relationships to Disclose
 
Petros Grivas
Consulting or Advisory Role - 4D Pharma; Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Dyania Health; EMD Serono; Exelixis; Genentech; GlaxoSmithKline; Guardant Health; Immunomedics; Infinity Pharmaceuticals; Janssen; Merck; Mirati Therapeutics; Pfizer; QED Therapeutics; Regeneron; Roche; Seagen
Research Funding - Bavarian Nordic (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Debiopharm Group (Inst); EMD Serono (Inst); GlaxoSmithKline (Inst); Immunomedics (Inst); Kure It Cancer Research (Inst); Merck (Inst); Mirati Therapeutics (Inst); Pfizer (Inst); QED Therapeutics (Inst)
 
Evan Y. Yu
Consulting or Advisory Role - Advanced Accelerator Applications; Bayer; Clovis Oncology; Exelixis; Janssen; Merck
Research Funding - Bayer (Inst); Blue Earth Diagnostics (Inst); Daiichi Sankyo (Inst); Dendreon (Inst); Lantheus Medical Imaging (Inst); Merck (Inst); Seagen (Inst); Taiho Pharmaceutical (Inst)
 
Robert B. Montgomery
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Beigene (Inst); Clovis Oncology (Inst); Janssen Oncology (Inst)
 
Andrew Caleb Hsieh
Honoraria - Hotspot Therapeutics
Patents, Royalties, Other Intellectual Property - MTOR modulators and uses thereof Patent number: 9629843; USE OF TRANSLATIONAL PROFILING TO IDENTIFY TARGET MOLECULES FOR THERAPEUTIC TREATMENT Publication number: 20140288097
 
Todd Yezefski
Consulting or Advisory Role - Dendreon
 
Michael Thomas Schweizer
Consulting or Advisory Role - AstraZeneca; PharmaIn; Resverlogix
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); ElevateBio (Inst); Immunomedics (Inst); Immunomedics (Inst); Janssen (Inst); Madison Vaccines, Inc. (Inst); Merck (Inst); Pfizer (Inst); Roche (Inst); Tmunity Therapeutics, Inc. (Inst); Zenith Epigenetics (Inst)
 
Sarah P. Psutka
Honoraria - Prime Education
Consulting or Advisory Role - Nucleix
Research Funding - Prime Education
Travel, Accommodations, Expenses - Prime Education